Feed HNSBF
HN

Hansa Biopharma AB (publ) HNSBF OTC · Healthcare · Sweden

$3.29 +0.00% +$0.00

Summary

46 / 100 · Bulios Score

What speaks for it

  • It holds more cash than debt: 1.34B kr against 952.3M kr.
  • Revenue grew by 13% a year over the last 3 years.
  • Out of every 100 SEK of revenue, 156 SEK is left as free cash.
  • Analysts expect revenue to grow by 21% this fiscal year.

What to watch

  • The company made a loss over the last 12 months.
  • The share price is above the Bulios Fair Price.
  • It missed profit estimates 7 times in the last 8 quarters.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today $3.29

By our assumptions the business is worth less than its shares cost today.

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

Yes, fast

Revenue (SEK)

Diluted EPS (SEK)

  • Analyst estimate

Revenue grew by 105% a year over 5 years. Over the last 3 years it grew by 13% a year. For the next fiscal year analysts expect revenue to grow by 21%.

Growth in detail

Does it make money?

Reasonably

Over the last 12 months it made a loss of 790.1M kr.

Profitability in detail

Is it financially healthy?

Yes

Repaying all its debt would take 2.1 years of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy